Chronic Lymphocytic Leukaemia: KOL Insight
In the last few years the emergence of new targeted therapies such as AbbVie’s/Janssen’s kinase inhibitor Imbruvica (ibrutinib) and Gilead’s P13K inhibitor Zydelig (idelalisib) have delivered effective therapies to previously underserved markets. Yet the arrival of AbbVie’s/Roche’s venetoclax looks to be a further game changer with its ability to induce complete remissions within a fixed treatment window. What impact will this new therapy have on the competitive landscape? How might it change the treatment paradigm and how do KOLs see it changing clinical practice?
This comprehensive report reveals critical insights from 12 leading North American and European KOLs – see who they are. Find outhow they view the clinical benefits of current and late stage products, potential drug combinations, and the patient’s condition state and financial concerns that determine therapy choice. See what marketed and pipeline drugs are discussed in the report - click here
Reasons to Purchase
Answering key questions
Key issues explored
- With biosimilar rituximab on the horizon, can Roche successfully protect Rituxan/MabThera revenues, and if so, how?
- What combinations are seen by KOLs as key to Roche’s Gazyva/Gazyvaro (obinutuzumab) future competitiveness?
- Is there a place for Novartis’ Arzerra (ofatumumab) in the treatment paradigm. And if so, where does it fit in?
- While AbbVie’s/Janssen’s Imbruvica (ibrutinib) dominates the market for patients with relapsed or refractory CLL, the high cost and indefinite duration of treatment is limiting growth – how can AbbVie/Janssen respond as competition grows?
- What are the prospects for Infinity’s/AbbVie’s duvelisib and Celgene’s lenalidomide pipeline therapies?
- Where do KOLs see Roche’s/AbbVie’s impressive venetolax (ABT-199) finding a place in the treatment paradigm now and in the future
- How might the treatment algorithm for high-risk CLL patients with the TP35 defect change and which therapies could move into the first-line setting?
- Critical factors affecting prescribing decisions: Know the detailed opinions of the leading KOLs on current and late stage CLL therapies and what they see as the critical clinical advantages/disadvantages affecting their decision to prescribe
- The significance of genetic risk factors: Appreciate the role genetic risk factors and co-morbidities play in determining treatment choice and identify key areas for strategic and tactical action
- Combination therapies and the treatment paradigm: Understand how combination therapy fits into the treatment paradigm and identify the products that will be positively or adversely affected
- Exclusive KOL opinion into current clinical trials: Review KOL attitudes to recently completed or ongoing clinical trials such as HELIOS, CLL11, COMPLEMENT 1 and RESONATE-2
Features of the report
- Formulate effective strategies for product positioning, pricing and clinician messaging
- Map new treatment options to CLL patients and patient sub-groups and identify niche opportunities
- Identify product attributes and patient characteristics that the KOLs think are the most important in terms of prescribing decisions and position in the treatment algorithm
- Appreciate the growing concern with drug prices and the negative effect it is having on uptake
- Discover which clinical trials the KOLs believe will have a significant impact on future treatment decisions and their likely outcomes
- Evaluate the changing and challenging competitive landscape as wider clinical adoption and experience with new products impacts prescribing choice
KOL Panel KOLs from North America:
- Knowledgeable “real-world” opinions of leading US and European KOLs that is not available in any other report
- Detailed and candid views on the future positioning and competitiveness of current and upcoming CLL therapies
- Essential insights that answer critical business questions and provide a platform for strategic planning and tactical engagement.
KOLs from Europe:
- Steve Coutre, MD, Professor Hematologist, Stanford Cancer Center, Stanford, CA, USA.
- Bruce Cheson, MD, FACP, FAAS, Professor of Medicine, Georgetown University Hospital, Lombardi Comprehensive Cancer Center, Washington DC, USA.
- Steven T. Rosen, MD, provost and chief scientific officer for City of Hope, Duarte, CA, USA.
- Farhad Ravandi, MD, Professor and Chief, Section of Developmental Therapeutics within the Department of Leukemia, Division of Cancer Medicine at MD Anderson, Houston, TX, USA.
- David Spaner, MD, FRCPC, PhD, Associate Professor and Senior Scientist Sunnybrook Health Sciences Centre, Odette Cancer Centre, University of Toronto, Canada.
- Anonymous US KOL, Associate Professor of Haematology in the Division of Medical Haematology at a large US academic medical center.
Get detailed KOL views on:
- Christopher Fegan Clinical Professor, Institute of Cancer & Genetics, Cardiff University School of Medicine, Cardiff, UK.
- Anonymous German KOL, Associate Professor and deputy chairman at the Department of Internal Medicine (Haematology, Oncology, Rheumatology and Infectious Diseases) at a University in Germany.
- Anonymous German KOL, Assistant professor and consultant at a large university hospital, Germany.
- Paolo Ghia, MD, Associate Professor in Internal Medicine at the Università Vita-Salute San Raffaele; and Deputy Chairman of the Division of Experimental Oncology, San Raffaele Scientific Institute, Italy.
- Fortunato Morabito, Contract professor for the Clinical Pathology Specialization program of the Faculty of Pharmacy, University of Calabria, Italy.
- Marco Montillo, MD, Director of Chronic Lymphoproliferative Disorders Program at the Department of Hematology of Niguarda Cancer Center, Niguarda Cà Granda Hospital in Milan, Italy.
NON-BIOLOGICAL TARGETED THERAPIES
- Marketed drugs
- Rituxan/MabThera (rituximab; Roche/Genentech/Biogen)
- Gazyva/Gazyvaro (obinutuzumab; Roche)
- Arzerra (ofatumumab; Novartis)
- Campath/MabCampath (alemtuzumab; Sanofi)
- Pipeline drugs
- ublituximab (TG-1101; TG Therapeutics)
- Marketed drugs
- Imbruvica (ibrutinib; AbbVie/Janssen Biotech)
- Zydelig (idelalisib; Gilead Sciences)
- Pipeline drugs
- venetoclax (ABT-199; Roche/AbbVie)
- duvelisib (IPI-145; Infinity/AbbVie)
- Revlimid (lenalidomide; Celgene)
- 1. Executive summary
- 2. Research Objectives
- 3. Research Focus
- 4. Chemotherapy Overview
- 5. Monoclonal antibodies
- 5.1. Marketed drugs
- 5.2. Rituxan/MabThera (rituximab; Roche/Biogen Idec)
- 5.3. Gazyva/Gazyvaro (obinutuzumab; Roche)
- 5.4. Arzerra (ofatumumab; Novartis)
- 5.5. Campath/MabCampath (alemtuzumab; Sanofi)
- 5.6. Pipeline drugs
- 5.7. Ublituximab (TG-1101; TG Therapeutics)
- 6. Non-biological targeted therapies
- 6.1. Marketed drugs
- 6.2. Imbruvica (ibrutinib; AbbVie/Janssen Biotech)
- 6.3. Zydelig (idelalisib; Gilead Sciences)
- 6.4. Pipeline drugs
- 6.5. Venetoclax (ABT-199; Roche/AbbVie)
- 6.6. Duvelisib (IPI-145; Infinity/AbbVie)
- 6.7. Revlimid (lenalidomide; Celgene)
- 6.8. Current and future treatment algorithms
- 6.9. Current and future treatment algorithm for CLL patients with low comorbidity burden
- 6.10. Current and future treatment algorithm for CLL patients with high comorbidity burden
- 6.11. Current and future treatment algorithm for CLL patients with genetic high‑risk markers
- 7. Appendix
- 7.1. KOL biographies
- 7.2. KOLs from North America
- 7.3. KOLs from Europe